for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent gets $23 mln additional order for vaccine production

April 4 (Reuters) - Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million.

The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.

Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance. (Reporting by Juby Babu in Bengaluru; Editing by Shailesh Kuber)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up